Are those symmetrical grey-brown cheekbone patches really melasma?

If you've been managing symmetrical patches over both cheekbones as melasma for years and they don't seem to budge, you're dealing with a question that comes up in pigmentation consultations more than you'd expect. The patches look close enough to melasma that the assumption makes sense — but the lack of response is a meaningful signal.

What's often happening in these cases is a depth problem. Melasma involves pigment that has increased in the epidermis, the outermost skin layer. The grey-brown patches that sit symmetrically across both cheekbones sometimes belong to a different category altogether: pigment cells that aren't in the epidermis at all, but in the dermis underneath it. That deeper location changes everything about how the patches look, why they don't respond to topical approaches, and what order of care makes sense.

This article walks through the clinical criteria that distinguish the two conditions, what the research tells us about treatment outcomes and timing, and what's worth documenting before your consultation.

This article organizes treatment information from Beautystone Clinic. Individual results vary, so discuss whether a procedure suits you with a dermatologist.

Why melasma management sometimes doesn't reach the right layer

Why melasma management sometimes doesn't reach the right layer

The word melasma covers a lot of ground, and it's often applied to any brownish pigmentation across the cheeks. The problem is that the area over the cheekbones is also where a distinct condition appears: acquired bilateral nevus of Ota-like macules, known clinically as ABNOM or Hori's nevus. Both conditions can produce brownish-looking discoloration across the cheeks, but they come from different depths in the skin.

Dermal melanocytes: pigment cells located in the dermis rather than the epidermis; because light passes through the overlying dermis before reaching them, they appear grey-blue or ashy rather than warm brown at the skin surface.

A cross-sectional dermatoscopy study at a Thai university dermatology clinic compared 50 melasma patients with 46 Hori's nevus patients using a polarized handheld dermatoscope, with two blinded dermatologists reading the results (PMC8944292). The differences were striking. Light brown pigmentation was seen in 98% of melasma patients but only 10.9% of Hori's nevus patients. Blue-brown or grey pigmentation appeared in 63% of Hori's nevus patients and in none of the melasma group. Follicle and sweat-gland sparing — where the pores appear to stand out as lighter dots against a darker background — was present in 98% of melasma patients but only 4.3% of the Hori's nevus group. A speckled homogeneous pattern appeared in 52.2% of Hori's nevus patients and zero melasma patients.

These patterns look different under a dermatoscope, and some of those differences are visible even to the naked eye. The grey or ashy tint, the way pores don't seem to be spared in the pattern, and the tendency to cluster in small dots rather than merging into a smooth field are all telling signals.

Why melasma management sometimes doesn't reach the right layer

Five criteria that separate malar grey-brown patches from melasma

Five criteria that separate malar grey-brown patches from melasma

The two conditions share a cheek location and a tendency toward bilateral distribution, but they diverge across several measurable characteristics. Clinicians typically look at five things.

Onset age adds another layer. A comparative clinical and histopathological analysis of 47 ABNOM patients and 35 nevus of Ota patients found that about 94% of ABNOM cases appeared after age 15, with a mean onset age of 36; the cohort's mean age was 41.5 years (PMC2816890). ABNOM distributed bilaterally across the forehead, temples, eyelids, cheeks, and nose; by contrast, nevus of Ota tended to be unilateral and also involved the ocular and oral mucosa. Histologically, ABNOM melanocytes sat in the superficial dermis, which explains the characteristic grey-blue tone.

A case report of a 20-year-old woman with pigmentation that began at age 8 — bilateral, symmetrical blue-violet macules across the malar region, nasal wings, and lower bulbar conjunctiva, with oral mucosa unaffected — found melanocytes clustered perivascularly in the papillary dermis with melanophages extending into the reticular dermis (PMC11345085). That perivascular clustering is one of the features used to distinguish the condition from melasma, which is typically epidermal, and from nevus of Ota, where the melanocytes spread in a more diffuse rather than clustered pattern. If the patches are unilateral and extend to mucous membranes, the differential shifts.

How Beautystone Clinic approaches the depth question before designing a pigmentation plan

How Beautystone Clinic approaches the depth question before designing a pigmentation plan

Depth comes before diagnosis labels. When both conditions are present at the same site — which isn't rare — treating them as a single entity tends to improve one layer while leaving the other unchanged. That's the scenario where someone has been doing everything right for years and the patches stay put: the management was reaching one depth and the persistent pigment was sitting in the other.

When epidermal pigment is dense on top, it scatters light and reduces the effectiveness of approaches aimed at the dermal layer beneath. Conversely, leaving dermal pigment unaddressed while clearing the surface can leave an ashy grey quality that the patient continues to perceive as discoloration. The sequence — which layer needs attention first — is a clinical decision that shapes the plan more than the individual ingredient choices.

Concurrent melasma changes the approach significantly. A retrospective study of 110 ABNOM patients treated with a 1064 nm Q-switched Nd:YAG laser over a three-year period found that when melasma co-existed, the fluence was reduced to 2.8–4.0 J/cm² from the standard 2.8–8.0 J/cm² range (PMC10155852). Even with that adjustment, 50% of patients with concurrent melasma experienced melasma aggravation. Post-inflammatory hyperpigmentation occurred in 10% of the full group. This isn't a reason to avoid treatment — it's a reason to map out what's present, set expectations around monitoring, and build the interval and intensity of each session around what's actually happening at both depths.

The session-by-session timeline matters too. In the same study, good-to-excellent improvement was reported by 28.1% of patients after two sessions, 50% after three, 70% after four, and 92.3% after five or more. A plan that treats a limited number of sessions as the full story will consistently underestimate the outcome potential.

How Beautystone Clinic approaches the depth question before designing a pigmentation plan

What to document before a pigmentation consultation

What to document before a pigmentation consultation

A few things you can prepare in advance make it easier to have a useful conversation in a limited time.

First, take photos under consistent conditions — natural or diffuse light, makeup-off, same camera height, both straight-on and at a 45-degree angle. Color tone is central to this assessment: overhead bathroom lighting can shift grey pigment toward brown, which changes the read. Consistent photos over time give you and the clinician something to compare.

Second, note when you first noticed the patches. Whether they appeared in your teens, emerged in your thirties, or came up around pregnancy or hormonal medication shifts is relevant to the depth question. ABNOM typically appears after age 15, with a mean onset in the mid-thirties; melasma is more closely associated with hormonal triggers.

Third, write down which topical approaches you've used and for how long, and whether any of them produced a visible response. Topicals that work on epidermal pigment won't reach dermal melanocytes. If you've used high-quality brightening agents consistently for an extended period without movement, that's itself a piece of clinical information — it suggests the persistent pigment may not be primarily epidermal.

Fourth, if you've had any laser or energy-based treatments for pigmentation before, note the timing, the treatment area, and whether the patches darkened afterward. Post-inflammatory hyperpigmentation occurred in 63.8% of ABNOM patients in one clinical study versus 31.4% of nevus of Ota patients (p<0.0001), making prior pigmentation response history an important planning input.

Getting the framework straight before your next step

Getting the framework straight before your next step

The patches sitting over both cheekbones may be melasma, ABNOM, or both at the same time — and the proportion of each shapes the plan. Symmetry across both cheekbones, a grey or ashy color tone, a speckled distribution without follicle sparing, and an adult onset age are the key signals pointing toward a dermal component.

Three things are worth confirming before a consultation: when the patches first appeared, how symmetrically they're distributed across both sides, and whether there's concurrent melasma at the same site. With those three pieces in hand, the question of what to address first becomes much more tractable than it is when the whole area is managed as a single pigmentation type.

Years of careful management without progress isn't a sign that the approach wasn't diligent. It's often a sign that the target depth didn't match the pigment depth — and that's a recalibration problem, not a fundamental limitation. Starting with depth and sequence rather than a diagnosis label tends to get to a clearer answer faster.